EUVIMEDEUVIMED entdecken
CrossrefInfokarte

Anti-Transcriptional Intermediary Factor 1 Gamma Antibody-Positive Dermatomyositis Concomitant with Diffuse Large B-Cell Lymphoma: Case Report and Literature Review

Hajime Yasuda, Midori Ishii, Kyohei Maruyama, Yuki Sano, Yuko Kojima, Yoshiyuki Abe, Shintaro Kinoshita, Yasuharu Hamano, Jun Ando, Miki Ando

Case Reports in Oncology · 2026-08-27 · 19 (1) · 1451-1458

DOI: 10.1159/cro/abzag037 ↗
AbstractBibliografische Angaben

Abstract

Introduction: Anti-transcriptional intermediary factor 1 gamma antibody-positive dermatomyositis (anti-TIF1-γ-DM) is a paraneoplastic syndrome occurring in various neoplasms, but reports elaborating on anti-TIF1-γ-DM patients accompanied by lymphoma are scarce. We report 2 patients with diffuse large B-cell lymphoma (DLBCL) complicated by anti-TIF1-γ-DM and carried out TIF1-γ immunohistochemistry on tissue sections of DLBCL and skin of anti-TIF1-γ-DM patients and controls. Genetic analysis of exons 2 and 10 of TRIM33, the gene coding TIF1-γ, was also carried out in DLBCL and skin samples of anti-TIF1-γ-DM patients and controls to look for recurrent mutations. Case Presentation: Case 1 was a 65-year-old male and case 2 was a 52-year-old male, and both patients presented with DLBCL complicated by anti-TIF1-γ-DM. R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisolone) therapy led to remissions of both anti-TIF1-γ-DM and DLBCL in both cases. Immunohistochemistry showed strong TIF1-γ expression in DLBCL and skin samples from both patients with anti-TIF1-γ-DM and controls. Mutations in exons 2 and 10 of TRIM33 have been previously reported in DLBCL cells of an anti-TIF1-γ-DM patient, but analysis of the same exons revealed no recurrent mutations in our cases. Conclusion: Anti-TIF1-γ-DM very often presents with a concomitant neoplasm, and a systemic evaluation for malignancy including lymphoma is mandatory. The etiology of anti-TIF1-γ-DM in patients with lymphoma remains unknown, and the underlying mechanisms have yet to be elucidated.

Wissen, das zu Ihrer Arbeit passt.

Vom kostenlosen Einstieg über die persönliche Recherche bis zur vollständigen Research Suite.

Tarife ansehen →

Sind alle Verlagsvolltexte enthalten?

Nein. Bibliografische Nachweise, Abstracts und Volltexte sind unterschiedliche Inhalte. Ob ein Volltext verfügbar ist, hängt von der Quelle, Open Access und Ihren vorhandenen Lizenzen ab. Ein EUVIMED-Tarif ersetzt keine zusätzlichen Verlagsrechte.

Tarife ansehen →